ABSTRACT
The term nonalcoholic fatty liver disease (NAFLD) has been used to describe a larger spectrum of steatosis liver diseases commonly associated with metabolic syndrome (MS) and represents a constellation of related health diseases. However, obesity-associated NAFLD was rst described nearly 50 years ago, and was only partially conrmed recently due to the complexity of the biochemical machine that
plays an important role between the inammatory process and cellular mechanisms of NAFLD-related diseases (Zivkovic et al., 2007).
